A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

June 16, 2014

Primary Completion Date

February 15, 2016

Study Completion Date

April 20, 2016

Conditions
Osteoporosis in Men
Interventions
BIOLOGICAL

Romosozumab

Administered by subcutaneous injection once a month.

DRUG

Placebo

Administered by subcutaneous injection once a month.

Trial Locations (34)

2750

Research Site, Ballerup Municipality

3000

Research Site, Leuven

3010

Research Site, Bern

3600

Research Site, Genk

4020

Research Site, Liège

8063

Research Site, Zurich

8091

Research Site, Zurich

9000

Research Site, Ghent

Research Site, Aalborg

20817

Research Site, Bethesda

21100

Research Site, Mexicali

64460

Research Site, Monterrey

80000

Research Site, Culiacán

80227

Research Site, Lakewood

87106

Research Site, Albuquerque

101990

Research Site, Moscow

150003

Research Site, Yaroslavl

190103

Research Site, Saint Petersburg

11001000

Research Site, Bogota

050021

Research Site, Medellín

722 00

Research Site, Ostrava-Trebovice

305 99

Research Site, Pilsen

148 00

Research Site, Praha 11 - Chodov

509-6134

Research Site, Mizunami-shi

223-0062

Research Site, Yokohama

879-7125

Research Site, Bungoono-shi

569-1123

Research Site, Takatsuki-shi

192-0046

Research Site, Hachioji-shi

140-0011

Research Site, Shinagawa-ku

171-0033

Research Site, Toshima-ku

90-558

Research Site, Lodz

21-040

Research Site, Świdnik

01-192

Research Site, Warsaw

50-088

Research Site, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY